Bausch + Lomb Corporate Developments – 12 October 2026

Bausch + Lomb Corporation (TSX: BLC), a global eye‑health company, announced a leadership change on 12 October 2026. Thomas J. Appio was named interim chief executive officer (CEO), succeeding the previous CEO, Michael Saunders, who resigned. The appointment was reported by several financial news outlets, including Seeking Alpha, Investing.com, and CEOCa. The transition is part of a broader strategic review of the company’s operations and guidance.

Interim CEO Appointment

  • Date of appointment: 12 October 2026
  • New interim CEO: Thomas J. Appio
  • Previous CEO: Michael Saunders (resigned)
  • Announcement sources:
  • Seeking Alpha (11:42 UTC)
  • Investing.com (11:06 UTC)
  • De.Investing.com (10:58 UTC)
  • CEOCa (10:45 UTC)
  • PRNewswire (12:00 UTC)

The appointment was made by the company’s board and is described as a temporary measure pending the selection of a permanent CEO.

Guidance Update

Alongside the leadership change, Bausch + Lomb released an updated full‑year 2026 outlook. The company indicated it intends to raise its guidance for the year, citing improved operational performance and a clearer focus on high‑margin business lines. The guidance hike is expected to have a positive impact on investor sentiment, although the company’s price‑earnings ratio remains negative at –35.99, reflecting its current earnings situation.

Company Context

  • Sector: Health Care
  • Primary Exchange: Toronto Stock Exchange (TSX)
  • Currency: CAD
  • Market Capitalisation: 8,811,267,072 CAD
  • Stock Performance (as of 8 Oct 2026):
  • Close price: 24.74 CAD
  • 52‑week high: 25.70 CAD (24 Feb 2026)
  • 52‑week low: 20.25 CAD (2 Jun 2026)

Bausch + Lomb operates globally, offering eye care products, ophthalmic pharmaceuticals, contact lenses, lens‑care solutions, and surgical devices. The company’s official website is www.bausch.ca .

While the CEO transition and guidance update are the primary focus, Bausch + Lomb’s parent, Bausch Health Companies Inc. (NYSE:BHC, TSX:BHC), announced a separate 6‑month pilot study in gastroenterology, demonstrating improved guideline adherence in cirrhosis care. The study, conducted in partnership with Salix Pharmaceuticals, will be presented at the American College of Gastroenterology Annual Scientific Meeting. Though unrelated to Bausch + Lomb’s core business, the initiative highlights the parent company’s commitment to evidence‑based healthcare improvements.